Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer

Biotechnol Adv. 2015 Jan-Feb;33(1):224-241. doi: 10.1016/j.biotechadv.2014.10.011. Epub 2014 Oct 31.

Abstract

Taxanes are one type of the most extensively used chemotherapeutic agents to treat cancers. However, their clinical use is severely limited by intrinsic and acquired resistance. A diverse variety of mechanisms has been implicated about taxane resistance, such as alterations of drug targets, overexpression of efflux transporters, defective apoptotic machineries, and barriers in drug transport. The deepening understanding of molecular mechanisms of taxane resistance has spawned a number of targets for reversing resistance. However, circumvention of taxane resistance would not only possess therapeutic potential, but also face with clinical challenge, which accelerates the development of optimal nanoscale delivery systems. This review highlights the current understanding on the mechanisms of taxane resistance, and provides a comprehensive analysis of various nanoscale delivery systems to reverse taxane resistance.

Keywords: Cancer; Multidrug resistance; Nanoparticles; Taxanes.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • ATP-Binding Cassette Transporters / metabolism
  • Antineoplastic Agents / pharmacology*
  • Apoptosis
  • Drug Delivery Systems / methods*
  • Drug Resistance, Neoplasm*
  • Humans
  • Nanoparticles / chemistry
  • Neoplasms / drug therapy*
  • Taxoids / pharmacology*
  • Tubulin / metabolism

Substances

  • ATP-Binding Cassette Transporters
  • Antineoplastic Agents
  • Taxoids
  • Tubulin